We are live on ! Find out more
N

Nuveen Portfolio holdings

AUM $369B
1-Year Est. Return 31.66%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$335B
AUM Growth
+$21B
Cap. Flow
-$4B
Cap. Flow %
-1.19%
Top 10 Hldgs %
21.52%
Holding
3,670
New
323
Increased
1,420
Reduced
1,524
Closed
323

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$1.66B
2
BABA icon
Alibaba
BABA
+$881M
3
INTC icon
Intel
INTC
+$783M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$783M
5
LIN icon
Linde
LIN
+$667M

Sector Composition

Rank Sector Weight
1 Technology 23.8%
2 Financials 13%
3 Consumer Discretionary 12.7%
4 Healthcare 12.61%
5 Communication Services 10.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NPKI
2501
NPK International
NPKI
$1.14B
$2.98M ﹤0.01%
860,338
+419,561
+95% +$1.42M
SRDX
2502
DELISTED
Surmodics
SRDX
$2.98M ﹤0.01%
54,850
-4,304
-7% -$236K
ACEL icon
2503
Accel Entertainment
ACEL
$987M
$2.97M ﹤0.01%
250,428
+71,268
+40% +$885K
UHT
2504
Universal Health Realty Income Trust
UHT
$594M
$2.97M ﹤0.01%
48,282
-2,711
-5% -$183K
UEIC icon
2505
Universal Electronics
UEIC
$61.3M
$2.97M ﹤0.01%
61,205
-13,759
-18% -$714K
VALE icon
2506
Vale
VALE
$62.6B
$2.94M ﹤0.01%
128,888
-1,080,273
-89% -$22.6M
CCXI
2507
DELISTED
ChemoCentryx, Inc.
CCXI
$2.94M ﹤0.01%
219,227
-253,488
-54% -$6.24M
KALV
2508
DELISTED
KalVista Pharmaceuticals
KALV
$2.93M ﹤0.01%
122,359
+39,269
+47% +$1.03M
RVI
2509
DELISTED
Retail Value Inc. Common Shares
RVI
$2.93M ﹤0.01%
1,468,404
-60,148
-4% -$107K
CLB icon
2510
Core Laboratories
CLB
$521M
$2.93M ﹤0.01%
75,177
+44,041
+141% +$1.58M
STTK icon
2511
Shattuck Labs
STTK
$694M
$2.93M ﹤0.01%
100,906
+44,493
+79% +$1.3M
RNAM
2512
DELISTED
Avidity Biosciences
RNAM
$2.92M ﹤0.01%
118,060
+21,804
+23% +$507K
ORBC
2513
DELISTED
ORBCOMM, Inc.
ORBC
$2.9M ﹤0.01%
257,563
-408,057
-61% -$4.53M
NIC icon
2514
Nicolet Bankshares
NIC
$3.62B
$2.89M ﹤0.01%
41,044
-4,352
-10% -$339K
RXRX icon
2515
Recursion Pharmaceuticals
RXRX
$1.73B
$2.87M ﹤0.01%
+78,730
New +$2.33M
UUUU icon
2516
Energy Fuels
UUUU
$3.53B
$2.86M ﹤0.01%
472,295
+10,133
+2% +$62.2K
RLGT icon
2517
Radiant Logistics
RLGT
$395M
$2.85M ﹤0.01%
410,800
-13,750
-3% -$99.5K
DADA
2518
DELISTED
Dada Nexus
DADA
$2.84M ﹤0.01%
+97,900
New +$2.54M
CSTE icon
2519
Caesarstone
CSTE
$79.5M
$2.84M ﹤0.01%
192,117
+17,204
+10% +$260K
GDYN icon
2520
Grid Dynamics Holdings
GDYN
$615M
$2.83M ﹤0.01%
188,157
-4,970
-3% -$77.9K
RGP icon
2521
Resources Connection
RGP
$145M
$2.82M ﹤0.01%
196,607
-9,438
-5% -$136K
FFIC
2522
DELISTED
Flushing Financial
FFIC
$2.82M ﹤0.01%
131,688
-6,765
-5% -$153K
SRG
2523
Seritage Growth Properties
SRG
$136M
$2.82M ﹤0.01%
153,304
-1,427
-0.9% -$25.3K
ARD
2524
DELISTED
Ardagh Group S.A. Class A Common Shares
ARD
$2.82M ﹤0.01%
114,871
+55,750
+94% +$1.44M
ANNX icon
2525
Annexon
ANNX
$886M
$2.81M ﹤0.01%
125,048
+38,184
+44% +$846K

Similar funds

Nuveen's Q2 2021 Portfolio in Review

As of Q2 2021, Nuveen held 3,670 positions worth $335B, up 6.7% from $314B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Nuveen's Q2 2021 filing shows 323 new, 1,420 increased, 1,524 reduced and 323 closed positions. Its largest new stake was UiPath: 2,457,331 shares worth $167M. The largest sale was Apple, an estimated $1.66B.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Nuveen's largest Q2 2021 buy was UiPath: 2,457,331 shares worth $167M.
  • Nuveen added most to Wells Fargo in Q2 2021, an estimated $512M increase.
  • Nuveen's biggest Q2 2021 reduction was Apple, cutting an estimated $1.66B.
  • Nuveen fully exited SolarEdge in Q2 2021, selling an estimated $66M.
  • Nuveen's ten largest holdings make up 22% of its $335B portfolio in Q2 2021.
  • Nuveen opened 323 new positions and closed 323 in Q2 2021.
  • Nuveen's portfolio value rose 6.7% quarter-over-quarter to $335B.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.